Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 22.0-999.0,  Essential Tremor Must be ≥22 years of age Competent and willing to provide written, informed consent to participate in the study A diagnosis of essential tremor as confirmed from clinical history and examination by a movement disorder neurologist A tremor severity score of 2 or above in the dominant hand/arm as measured by any one of the upper limb items and a minimum subset score of 6 across all upper limb items Significant disability due to essential tremor (Bain & Findley score of 3 or above in any one of the upper limb items and a minimum subset score of 8 across all upper limb items) Stable dose of tremor medications, if applicable, for 30 days prior to study entry Stable dose of antidepressant medications, if applicable, for 90 days prior to study entry Willing to comply with study protocol requirements including remaining on a stable dosage of tremor and antidepressant medications, if applicable, during the duration of the study no significant alcohol or caffeine consumption within 8 hours prior to study visits  Moderate to severe ethanol dependence as defined by the outlined in the DSM-5 (score of 4 or higher) Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator, or implanted metal in the wrist to be stimulated Previous thalamotomy procedure, including stereotactic thalamotomy, gamma knife radiosurgical thalamotomy, and focused ultrasound for the treatment of tremor Suspected or diagnosed epilepsy or other seizure disorder Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site Peripheral neuropathy affecting the tested upper extremity Presence of any other neurodegenerative disease like Parkinson-plus syndromes suspected on neurological examination. These multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease Anyone suspected to have the diagnosis of idiopathic Parkinson's disease (PD). This includes excluding anyone with the presence of parkinsonian features including bradykinesia rigidity, or postural instability. Subjects who exhibit only mild resting tremor but no other symptoms or signs of PD may be included Botulinum toxin injection for hand tremor within 6 months prior to study enrollment Are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor